Tecovirimat
As of the edition of 20 October 2026, Tecovirimat is a small molecule: marketed, first approved in 2018 (US); US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Tpoxx
- First approved
- 13 July 2018 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Japan Biotechno Pharma Co., Ltd.; 3 holders in all
- Registered trials
- 12, 2 stopped early
- Disease areas
- Infections; Animal diseases
US protection
US protection ends in 2031.
The last listed US drug-substance patent ends in 2031. The application that gives this date is held by SIGA Technologies.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 1 | 0 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 0 | 1 | 1 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| SIGA Technologies | Originator, Applicant and Lead sponsor of trials | 2007 to now |